With the emergence of multiple meningococcal serogroups in different geographic areas, broad
vaccine protection from infancy is desirable. One hundred and seventy-five infants received either two doses of a meningococcal quadrivalent (A, C, W-135, Y)
conjugate vaccine (
MenACWY-CRM) at 6 and 12 months, one dose of
MenACWY-CRM at 12 months, or MenC at 12 months and
MenACWY-CRM at 18 months. Bactericidal antibody titers using human
complement were measured before and 1 month after each dose.
Injection-site reactions were reported by 22-45% of participants following
MenACWY-CRM given at 6 or 12 months. Similar proportions of subjects had
injection-site reactions following two doses of
MenACWY-CRM (32-41%) or one dose of MenC (26-44%). The incidence of systemic adverse events was comparable between groups. After two doses of
MenACWY-CRM, the percentages of participants reporting hSBA titers >or=8 were 100% for C, W-135, and Y, and 84% for A. Serogroup C titers were more than 10-fold higher after two doses of
MenACWY-CRM than after one dose of MenC or
MenACWY-CRM at 12 months. Serogroup C titers were comparable following a single dose of
MenACWY-CRM or MenC at 12 months.
MenACWY-CRM is well tolerated and immunogenic given at 12 months, or two doses at 6 and 12 months of age.